http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
AgeX Therapeutics to Collaborate with University of California, Irvine on Neural Stem Cell Research Program for Huntington’s Disease and Other Neurological Disorders
-
AgeX Therapeutics Inc. (AGE) Enters Research Collaboration With Japanese Biopharma Company to Generate Hypoimmunogenic Cells
-
AgeX Therapeutics Enters Research Collaboration With Japanese Biopharma Company to Generate Hypoimmunogenic Cells
-
AgeX Therapeutics to Participate at Four Conferences in January 2020
-
AgeX Therapeutics Announces Drawdown of Second Tranche of Loan Facility from Juvenescence Ltd.
-
Lineage Cell Therapeutics (LCTX), AgeX Therapeutics (AGE) Announce Issuance of U.S. Patent for Method of Generating Induced Pluripotent Stem Cells
-
Lineage Cell Therapeutics and AgeX Therapeutics Announce Issuance of U.S. Patent for Method of Generating Induced Pluripotent Stem Cells
-
AgeX Therapeutics and Lineage Cell Therapeutics Announce Issuance of U.S. Patent for Method of Generating Induced Pluripotent Stem Cells
-
AgeX Therapeutics Issues Year-End Letter to Shareholders
-
AgeX Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update
-
Lineage Cell Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update
-
AgeX Therapeutics to Present at Investing in the Age of Longevity Conference
-
AgeX Therapeutics and Juvenescence Publish Paper on Engineering Strategies for Universal Cells and Provide in Vivo Observation on Immunotolerance UniverCyteTM Technology Platform
-
AgeX Therapeutics to Present at Metabesity 2019
-
AgeX Therapeutics Presents at the Rodman & Renshaw Global Investment Conference
-
AgeX Therapeutics Publishes Theoretical Basis of Human Cell Age-Reversal in the Journal Regenerative Medicine
-
AgeX Therapeutics, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update
-
BioTime Reports Second Quarter 2019 Financial Results and Provides Business Update
-
AgeX Therapeutics Inc. (AGE) Announces Michael H. May to Board
-
Regenerative Medicine Leader Michael H. May Joins AgeX Board of Directors
-
AgeX Therapeutics’ CEO Dr. Michael D. West to Present at Ending Age-Related Diseases: Investment Prospects & Advances in Research
-
AgeX Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update
-
AgeX Therapeutics to Participate at Biotech Investing in Longevity from Aikora Health and Foresight Institute
-
AgeX Therapeutics to Present at Master Investor Show 2019
-
AgeX Therapeutics Reports Fourth Quarter and Annual 2018 Financial Results and Provides Business Update
-
AgeX Therapeutics Receives $4.5 Million From Exercise of Warrants
-
AgeX Therapeutics to Present at Undoing Aging 2019, March 28-30 in Berlin, Germany
-
LifeMap Sciences and iCarbonX Research Shenzhen Announce Strategic Collaboration
-
BioTime Provides Business Update Including Information on AgeX, OncoCyte and Asterias
-
AgeX Therapeutics to Present at Longevity Leaders Conference, February 4 in London
-
AgeX Therapeutics’ CEO Dr. Michael D. West Presents at Precision Medicine World Conference 2019
-
LifeMap Sciences, Tianjin Novogene and Shanghai Shanyi Announce Strategic Partnership to Offer Leading Clinical NGS Solution to the China Market
-
AgeX Therapeutics Inc. (AGE) Reports Publication of Data in Peer-Reviewed Journal to Advance Potential Cell Therapy AgeX-BAT1 for Type II Diabetes and Obesity
-
AgeX Therapeutics Publishes Data in Peer-Reviewed Journal to Advance Potential Cell Therapy AgeX-BAT1 for Type II Diabetes and Obesity
-
BioTime Announces Management Changes Concurrent With Participation at 2019 J.P. Morgan Healthcare Conference and 2019 Biotech Showcase
-
BioTime to Present at 2019 Biotech Showcase Investor Conference on January 7, 2019
-
AgeX Therapeutics to Present at Biotech Showcase 2019
-
AgeX Therapeutics, Inc. to Present Keynote Address at Advanced Stem Cell & Regenerative Medicine 2018 Conference
-
AgeX Therapeutics, Inc. Shares Commence Trading on the NYSE American
-
Shareholders of Adventure Gold and Superior Court of Quebec Approve Arrangement with Probe Metals
-
Adventure Gold Files Information Circular Seeking Shareholder Approval for Business Combination With Probe Metals
-
Adventure Gold Commences a New Drilling Program on Its 100%-Owned Detour Quebec North Project
-
Adventure Gold and SOQUEM Commence a First Drilling Program on Lower Detour Gold Trend
-
Adventure Gold Closes a Private Placement
-
Adventure Gold Closes $725,025 Private Placement
-
Adventure Gold Options a Part of Its Detour Quebec Project to SOQUEM
-
Adventure Gold Cuts 10.6 g/t Au Over 11.5 Metres in Channel Sampling on the New Beliveau Gold Deposit - Val-d'Or East, Quebec
-
Adventure Gold Completes Mechanical Stripping and Drone Surveying on the New Beliveau Gold Deposit - Val-d'Or East, Quebec
-
Adventure Gold Outlines Promising IP Anomalies Along the Lower Detour Gold Trend and Releases Results from its First Drill Program on the Detour Quebec Properties
-
Adventure Gold and GFK Resources Amend the Casa-Cameron Option Agreement and Announce 2015 Exploration Program

